Hannah Joseph Hospital IPO GMP, Financials & Review: Apply or Skip?

Hannah Joseph Hospital IPO has opened for subscription from January 22 to January 27, 2026. This is a ₹42 crore bookbuilding SME IPO, consisting entirely of a fresh issue of 60 lakh shares. The IPO is priced in the range of ₹67 to ₹70 per share, with a face value of ₹10. The shares are proposed to be listed on the BSE SME platform on January 30, 2026.

Hannah Joseph Hospital IPO GMP

As of January 22, 2026, the Grey Market Premium (GMP) of Hannah Joseph Hospital IPO stands at ₹0. This indicates a flat listing expectation, with an estimated listing price close to the upper issue price of ₹70. While GMP remains an important sentiment indicator, it can change quickly based on market conditions.

Financial Performance

Hannah Joseph Hospital Limited has shown strong financial growth in recent years. The company’s revenue increased by 51.70%, rising from ₹63.63 crore in FY24 to ₹77.90 crore in FY25. Profit After Tax (PAT) also grew significantly by 41.52%, reaching ₹7.21 crore in FY25. This consistent growth highlights improving operational efficiency and financial stability.

Key Valuation Metrics

At the upper price band, the IPO is valued at a P/E ratio of around 16.21, which is reasonable compared to peers in the healthcare SME space. The company reports an EPS of 4.32, ROE of 9.39%, and ROCE of 10.41%, indicating moderate but stable returns.

About the Company

Established in 2011, Hannah Joseph Hospital Limited operates a 150-bed multi-speciality hospital in Madurai, Tamil Nadu. The hospital focuses on Neurology, Cardiology, Psychiatry, Orthopaedics, and Trauma Care, supported by modern infrastructure and a team of over 360 employees.

IPO Objectives

The company plans to use the IPO proceeds mainly for:

• Setting up a Radiation Oncology Centre
• Meeting general corporate expenses

Apply or Skip?

Hannah Joseph Hospital IPO offers steady financial growth, a reasonable valuation, and exposure to the growing healthcare sector. However, zero GMP, regional concentration, and execution risks related to expansion may limit short-term listing gains.

Risk-averse investors may consider waiting, while long-term investors with moderate risk appetite can evaluate applying after considering overall market sentiment.